Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

• DOI: 10.3816/clc.2009.n.035
• Publication Date: 2009-07-26T01:06:08Z
• Authors: Jyoti D. Patel; Philip Bonomi; Mark A. Socinski; Ramaswamy Govindan; Shengyan Hong; Coleman Obasaju; Eduardo J. Pennella; Allicia C. Girvan; Susan C. Guba
• Keywords: Guanine; Lung Neoplasms; Paclitaxel; Antibodies, Monoclonal; Pemetrexed; Antibodies, Monoclonal, Humanized; Prognosis; Disease-Free Survival; Drug Administration Schedule; Carboplatin; 3. Good health; Bevacizumab; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Glutamates; Carcinoma, Non-Small-Cell Lung; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Humans

We present the treatment rationale and study design of the PointBreak study, a phase III study of pemetrexed/ carboplatin/bevacizumab induction followed by pemetrexed/bevacizumab maintenance (arm A) compared with paclitaxel/carboplatin/bevacizumab induction followed by bevacizumab maintenance (arm B) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). Treatment consists of up to 4 cycles of induction therapy followed by maintenance therapy until disease progression or treatment discontinuation in approximately 900 patients (450 per treatment arm). The efficacy objectives of this study are to compare overall survival (OS), response rates, disease control rates, progression-free survival, and time to progressive disease between the 2 treatment arms. In addition, safety, quality of life, pharmacokinetics, and translational research will be investigated for both treatment arms. If the primary objective (OS) is achieved, this study will provide robust results on an alternative treatment option, pemetrexed/carboplatin/bevacizumab followed by maintenance therapy with pemetrexed/bevacizumab, for patients with nonsquamous NSCLC.